387 related articles for article (PubMed ID: 28592566)
1. Combined immune checkpoint blockade as a therapeutic strategy for
Nolan E; Savas P; Policheni AN; Darcy PK; Vaillant F; Mintoff CP; Dushyanthen S; Mansour M; Pang JB; Fox SB; ; Perou CM; Visvader JE; Gray DHD; Loi S; Lindeman GJ
Sci Transl Med; 2017 Jun; 9(393):. PubMed ID: 28592566
[TBL] [Abstract][Full Text] [Related]
2. The anti-cancer immune response in breast cancer: current and emerging biomarkers and treatments.
Rayson VC; Harris MA; Savas P; Hun ML; Virassamy B; Salgado R; Loi S
Trends Cancer; 2024 Jun; 10(6):490-506. PubMed ID: 38521654
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral Administration of a Novel Cytotoxic Formulation with Strong Tissue Dispersive Properties Regresses Tumor Growth and Elicits Systemic Adaptive Immunity in In Vivo Models.
Bender LH; Abbate F; Walters IB
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32599852
[TBL] [Abstract][Full Text] [Related]
4. Loss of NEDD8 in cancer cells causes vulnerability to immune checkpoint blockade in triple-negative breast cancer.
Papakyriacou I; Kutkaite G; Rúbies Bedós M; Nagarajan D; Alford LP; Menden MP; Mao Y
Nat Commun; 2024 Apr; 15(1):3581. PubMed ID: 38678024
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibition for Triple-Negative Breast Cancer: Current Landscape and Future Perspectives.
Yi H; Li Y; Tan Y; Fu S; Tang F; Deng X
Front Oncol; 2021; 11():648139. PubMed ID: 34094935
[TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects.
Thomas R; Al-Khadairi G; Decock J
Front Oncol; 2020; 10():600573. PubMed ID: 33718107
[TBL] [Abstract][Full Text] [Related]
7. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Le DT; Durham JN; Smith KN; Wang H; Bartlett BR; Aulakh LK; Lu S; Kemberling H; Wilt C; Luber BS; Wong F; Azad NS; Rucki AA; Laheru D; Donehower R; Zaheer A; Fisher GA; Crocenzi TS; Lee JJ; Greten TF; Duffy AG; Ciombor KK; Eyring AD; Lam BH; Joe A; Kang SP; Holdhoff M; Danilova L; Cope L; Meyer C; Zhou S; Goldberg RM; Armstrong DK; Bever KM; Fader AN; Taube J; Housseau F; Spetzler D; Xiao N; Pardoll DM; Papadopoulos N; Kinzler KW; Eshleman JR; Vogelstein B; Anders RA; Diaz LA
Science; 2017 Jul; 357(6349):409-413. PubMed ID: 28596308
[TBL] [Abstract][Full Text] [Related]
8. Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer.
Ganesan AP; Clarke J; Wood O; Garrido-Martin EM; Chee SJ; Mellows T; Samaniego-Castruita D; Singh D; Seumois G; Alzetani A; Woo E; Friedmann PS; King EV; Thomas GJ; Sanchez-Elsner T; Vijayanand P; Ottensmeier CH
Nat Immunol; 2017 Aug; 18(8):940-950. PubMed ID: 28628092
[TBL] [Abstract][Full Text] [Related]
9. De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation.
Ghoneim HE; Fan Y; Moustaki A; Abdelsamed HA; Dash P; Dogra P; Carter R; Awad W; Neale G; Thomas PG; Youngblood B
Cell; 2017 Jun; 170(1):142-157.e19. PubMed ID: 28648661
[TBL] [Abstract][Full Text] [Related]
10. Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing.
Zheng C; Zheng L; Yoo JK; Guo H; Zhang Y; Guo X; Kang B; Hu R; Huang JY; Zhang Q; Liu Z; Dong M; Hu X; Ouyang W; Peng J; Zhang Z
Cell; 2017 Jun; 169(7):1342-1356.e16. PubMed ID: 28622514
[TBL] [Abstract][Full Text] [Related]
11. Immune Escape in Breast Cancer During
Gil Del Alcazar CR; Huh SJ; Ekram MB; Trinh A; Liu LL; Beca F; Zi X; Kwak M; Bergholtz H; Su Y; Ding L; Russnes HG; Richardson AL; Babski K; Min Hui Kim E; McDonnell CH; Wagner J; Rowberry R; Freeman GJ; Dillon D; Sorlie T; Coussens LM; Garber JE; Fan R; Bobolis K; Allred DC; Jeong J; Park SY; Michor F; Polyak K
Cancer Discov; 2017 Oct; 7(10):1098-1115. PubMed ID: 28652380
[TBL] [Abstract][Full Text] [Related]
12. IFNγ-Dependent Tissue-Immune Homeostasis Is Co-opted in the Tumor Microenvironment.
Nirschl CJ; Suárez-Fariñas M; Izar B; Prakadan S; Dannenfelser R; Tirosh I; Liu Y; Zhu Q; Devi KSP; Carroll SL; Chau D; Rezaee M; Kim TG; Huang R; Fuentes-Duculan J; Song-Zhao GX; Gulati N; Lowes MA; King SL; Quintana FJ; Lee YS; Krueger JG; Sarin KY; Yoon CH; Garraway L; Regev A; Shalek AK; Troyanskaya O; Anandasabapathy N
Cell; 2017 Jun; 170(1):127-141.e15. PubMed ID: 28666115
[TBL] [Abstract][Full Text] [Related]
13. CDK4/6 inhibition triggers anti-tumour immunity.
Goel S; DeCristo MJ; Watt AC; BrinJones H; Sceneay J; Li BB; Khan N; Ubellacker JM; Xie S; Metzger-Filho O; Hoog J; Ellis MJ; Ma CX; Ramm S; Krop IE; Winer EP; Roberts TM; Kim HJ; McAllister SS; Zhao JJ
Nature; 2017 Aug; 548(7668):471-475. PubMed ID: 28813415
[TBL] [Abstract][Full Text] [Related]
14. Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer.
Dushyanthen S; Teo ZL; Caramia F; Savas P; Mintoff CP; Virassamy B; Henderson MA; Luen SJ; Mansour M; Kershaw MH; Trapani JA; Neeson PJ; Salgado R; McArthur GA; Balko JM; Beavis PA; Darcy PK; Loi S
Nat Commun; 2017 Sep; 8(1):606. PubMed ID: 28928458
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant Interferons: Critical for Effective PD-1-Based Immunotherapy in TNBC.
Brockwell NK; Owen KL; Zanker D; Spurling A; Rautela J; Duivenvoorden HM; Baschuk N; Caramia F; Loi S; Darcy PK; Lim E; Parker BS
Cancer Immunol Res; 2017 Oct; 5(10):871-884. PubMed ID: 28848054
[TBL] [Abstract][Full Text] [Related]
16. Breast Cancer Immunotherapy: Facts and Hopes.
Emens LA
Clin Cancer Res; 2018 Feb; 24(3):511-520. PubMed ID: 28801472
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function.
Lee YH; Martin-Orozco N; Zheng P; Li J; Zhang P; Tan H; Park HJ; Jeong M; Chang SH; Kim BS; Xiong W; Zang W; Guo L; Liu Y; Dong ZJ; Overwijk WW; Hwu P; Yi Q; Kwak L; Yang Z; Mak TW; Li W; Radvanyi LG; Ni L; Liu D; Dong C
Cell Res; 2017 Aug; 27(8):1034-1045. PubMed ID: 28685773
[TBL] [Abstract][Full Text] [Related]
18. Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features.
Sia D; Jiao Y; Martinez-Quetglas I; Kuchuk O; Villacorta-Martin C; Castro de Moura M; Putra J; Camprecios G; Bassaganyas L; Akers N; Losic B; Waxman S; Thung SN; Mazzaferro V; Esteller M; Friedman SL; Schwartz M; Villanueva A; Llovet JM
Gastroenterology; 2017 Sep; 153(3):812-826. PubMed ID: 28624577
[TBL] [Abstract][Full Text] [Related]
19. PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer.
Yearley JH; Gibson C; Yu N; Moon C; Murphy E; Juco J; Lunceford J; Cheng J; Chow LQM; Seiwert TY; Handa M; Tomassini JE; McClanahan T
Clin Cancer Res; 2017 Jun; 23(12):3158-3167. PubMed ID: 28619999
[No Abstract] [Full Text] [Related]
20. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
Kuchenbaecker KB; Hopper JL; Barnes DR; Phillips KA; Mooij TM; Roos-Blom MJ; Jervis S; van Leeuwen FE; Milne RL; Andrieu N; Goldgar DE; Terry MB; Rookus MA; Easton DF; Antoniou AC; ; McGuffog L; Evans DG; Barrowdale D; Frost D; Adlard J; Ong KR; Izatt L; Tischkowitz M; Eeles R; Davidson R; Hodgson S; Ellis S; Nogues C; Lasset C; Stoppa-Lyonnet D; Fricker JP; Faivre L; Berthet P; Hooning MJ; van der Kolk LE; Kets CM; Adank MA; John EM; Chung WK; Andrulis IL; Southey M; Daly MB; Buys SS; Osorio A; Engel C; Kast K; Schmutzler RK; Caldes T; Jakubowska A; Simard J; Friedlander ML; McLachlan SA; Machackova E; Foretova L; Tan YY; Singer CF; Olah E; Gerdes AM; Arver B; Olsson H
JAMA; 2017 Jun; 317(23):2402-2416. PubMed ID: 28632866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
